BMS Targets Fibrotic Disease with US$475 M Amira Pharmaceuticals Purchase
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 8 (Table of Contents)
Published: 2 Aug-2011
DOI: 10.3833/pdr.v2011.i8.1516 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Continuing its String of Pearls strategy of enhancing its pipeline via alliances and acquisitions, Bristol-Myers Squibb (BMS) has agreed to buy Amira Pharmaceuticals in a deal worth up to US$475 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS